An Elegan(t) Screen for Drug-Microbe Interactions

Alison Vrbanac; Justine W Debelius; Lingjing Jiang; James T Morton; Pieter Dorrestein; Rob Knight

doi:10.1016/j.chom.2017.04.014

An Elegan(t) Screen for Drug-Microbe Interactions

Cell Host Microbe. 2017 May 10;21(5):555-556. doi: 10.1016/j.chom.2017.04.014.

Authors

Alison Vrbanac¹, Justine W Debelius¹, Lingjing Jiang¹, James T Morton¹, Pieter Dorrestein², Rob Knight³

Affiliations

¹ Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
² Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA 92093, USA; Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA.
³ Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA; Center for Microbiome Innovation, University of California, San Diego, La Jolla, CA 92093, USA; Department of Computer Science and Engineering, University of California, San Diego, La Jolla, CA 92093, USA. Electronic address: [email protected].

PMID: 28494234
DOI: 10.1016/j.chom.2017.04.014

Abstract

Microbes affect drug responses, but mechanisms remain elusive. Two papers in Cell exploit C. elegans to infer anticancer drug mechanisms. Through high-throughput screens of drug-microbe-host interactions, García-González et al. (2017) and Scott et al. (2017) determine that bacterial metabolism underpins fluoropyrimidine cytotoxicity, providing a paradigm for unraveling bacterial mechanisms in drug metabolism.

MeSH terms

Animals
Antineoplastic Agents / pharmacology*
Bacteria / metabolism
Caenorhabditis elegans / microbiology*
Drug Discovery / methods*
High-Throughput Screening Assays / methods
Host-Pathogen Interactions / drug effects*
Models, Biological*

Substances

Antineoplastic Agents